Orbis Medicines, a biotech company based in Copenhagen, aims to develop peptide-based drugs that can be dosed orally, unlike traditional biologic drugs that require injection or infusion. Backed by €26 million in seed financing, Orbis’s technology platform enables the design of macrocycles with desired properties such as oral bioavailability and cellular permeability. These compounds have the potential to target challenging diseases that are currently treated with antibody drugs requiring inconvenient dosing. Orbis’s innovative approach, led by scientific co-founders Christian Heinis and Sevan Habeshian, could revolutionize drug delivery and offer new treatment options for patients with chronic conditions.
Source link
Startup Orbis Medicines Launches With €26M for Next-Generation Peptide Drugs
